. Author manuscript; available in PMC: 2014 Oct 24.

Published in final edited form as: J Med Chem. 2013 Oct 10;56(20):10.1021/jm401266k. doi: 10.1021/jm401266k

Table 11.

Antiviral activity of 19 and PF-00868554 against GT 1a and GT 1b NS5B clinical isolates.

GT	Isolate	Cmpd 19 EC₅₀ (nM)^a	PF-00868554 EC₅₀ (nM)^a
1a	H77	1.0±0.3	95.8±9.7
	RO-18	1.3±0.1	47.0±6.2
	RO-22	4.1±1.0	42.8±7.6
	RO-24	3.1±0.1	37.0±1.2
	RO-28	1.8±0.1	38.8±2.3
	RO-32	2.3±0.1	26.0±1.2
	RO-33	1.1±0.1	34.4±3.4
	RO-34	2.2±0.1	25.0±0.8
	RO-35	0.4±0.1	22.0±4.9
	RO-38	6.8±0.5	56.0±6.0
	RO-41	1.5±0.2	48.0±6.8
	(mean)^b	1.8	39.5
1b	Con1	1.4±0.3	51.1±11.2
	RO-1	0.5±0.1	39.3±3.0
	RO-2	0.7±0.1	21.3±4.9
	RO-3	1.7±0.4	28.5±7.2
	RO-4	0.4±0.1	25.5±7.4
	RO-7	1.8±0.7	20.8±5.4
	RO-8	2.0±0.2	18.7±4.8
	RO-9	3.0±0.1	23.5±6.9
	RO-10	2.8±0.1	39.7±7.2
	(mean)^b	1.3	28.2

EC₅₀ measured using transient HCV subgenomic replicon assay (n ≥ 2), nM±SEM (Standard Error)

calculated geometric mean.